Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roberto Diaz

Sleep Medicine Corpus Christi, TX Medical Doctor

NPI 1851300891 CMS profile 219501

7121 S Padre Island Dr Ste 104, Corpus Christi, TX 78412

Open in the dashboard

General payments

$7,276

511 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roberto Diaz of Corpus Christi, TX is reported in the CMS Open Payments database as having received $7,276 across 511 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2024 General $99 1
2023 General $31 2
2022 General $617 34
2021 General $831 69
2020 General $2,425 156
2019 General $3,254 248

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberto Diaz
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Roberto Diaz were reported at $19. Among 670 Sleep Medicine profiles paid that year, the median was $439 and the middle half received between $127 and $1,274.

Show as a table
Year Roberto Diaz Sleep Medicine median Middle half National median
2019 $3,254 $185 $66–$736 $163
2020 $2,425 $149 $46–$504 $114
2021 $831 $191 $62–$750 $132
2022 $617 $246 $92–$972 $149
2023 $31 $321 $119–$1,033 $160
2024 $99 $393 $111–$1,207 $164
2025 $19 $439 $127–$1,274 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,168 60 payments
  2. Novo Nordisk Inc $1,095 123 payments
  3. Amgen Inc. $447 28 payments
  4. Amarin Pharma Inc. $406 23 payments
  5. Pfizer Inc. $369 32 payments
  6. GlaxoSmithKline, LLC. $349 22 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $342 21 payments
  8. Merck Sharp & Dohme Corporation $315 24 payments
  9. Kowa Pharmaceuticals America, Inc. $292 16 payments
  10. Astellas Pharma US Inc $283 17 payments
  11. Other $2,211 145 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,188 506 payments
  2. Education $88 5 payments
Products named General payments · program years 2019–2025
  1. Ozempic $872 105 payments
  2. FARXIGA $810 43 payments
  3. RYBELSUS $646 77 payments
  4. JARDIANCE $342 21 payments
  5. AIMOVIG $296 18 payments
  6. Livalo $292 16 payments
  7. ENTRESTO $282 15 payments
  8. Vascepa $279 15 payments
  9. Repatha $278 17 payments
  10. Bystolic $244 13 payments
  11. Other $6,884 494 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

511 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record